Compare GSM & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | ZYME |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.0M | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | GSM | ZYME |
|---|---|---|
| Price | $4.62 | $25.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.00 | ★ $29.50 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,373,244,000.00 | $134,481,000.00 |
| Revenue This Year | N/A | $64.45 |
| Revenue Next Year | $22.56 | $67.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 116.21 |
| 52 Week Low | $2.97 | $9.03 |
| 52 Week High | $5.74 | $28.49 |
| Indicator | GSM | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 60.22 |
| Support Level | $4.42 | $24.79 |
| Resistance Level | $4.79 | $27.49 |
| Average True Range (ATR) | 0.20 | 1.27 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 82.54 | 36.74 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.